Remegen Co., Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3
Ending by 2030
Mar 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jul 21, 2027The maintenance fee for Covalent Linkers in Antibody-Drug Conjugates and Methods of Making and Using the Same (US 10,537,644) comes due Jul 21, 2027. Unpaid by Jan 21, 2028, it lapses early.
- 1 fee due Sep 1, 2027The maintenance fee for FGFR-Fc fusion proteins and the use thereof (US 9,273,137) comes due Sep 1, 2027. Unpaid by Mar 1, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,893,216 | Anti-human trail receptor DR5 monoclonal antibody (AD5-10), method thereof and use of the same In force · From the USPTO record | In force | From the USPTO record | |
| US 8,193,316 | TACI-Fc fusion proteins, methods of making and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 8,790,663 | Antigenic determinants of human death receptor DR5 In force · From the USPTO record | In force | From the USPTO record | |
| US 9,273,137 | FGFR-Fc fusion proteins and the use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,957,313 | FGFR-FC fusion proteins and the use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,522,949 | Fusion protein for antagonizing angiogenesis inducible factors and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,725,517 | Humanized monoclonal antibodies against the extracellular domain of human death receptor 5 In force · From the USPTO record | In force | From the USPTO record | |
| US 10,087,260 | Anti-HER2 antibody and conjugate thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,537,644 | Covalent Linkers in Antibody-Drug Conjugates and Methods of Making and Using the Same In force · High confidence | In force | High confidence | |
| US 10,772,965 | Covalent Linkers in Antibody-Drug Conjugates and Methods of Making and Using the Same In force · Medium confidence | In force | Medium confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
15 pending · 1 abandoned · 5 no status recorded